Laboratory Corporation of America Holdings Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Laboratory of America Holdings de 24.4% y 4.4% por año respectivamente. Se prevé que el BPA crezca en un 21.7% al año. Se espera que la rentabilidad financiera sea de 15.9% en 3 años.

Información clave

20.1%

Tasa de crecimiento de los beneficios

20.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	17.3%
Tasa de crecimiento de los ingresos	4.4%
Rentabilidad financiera futura	15.9%
Cobertura de analistas	Good
Última actualización	02 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Laboratory Corporation of America Holdings (NYSE:LH) Is Paying Out A Dividend Of $0.72

Apr 30

Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72

Apr 15

Laboratory Corporation of America Holdings' (NYSE:LH) P/E Is On The Mark

Apr 06

Laboratory Corporation: A Healthier Diagnosis, As Pandemic Headwinds Disappear

Apr 01

Laboratory Corporation of America Holdings (NYSE:LH) Will Pay A Dividend Of $0.72

Feb 25

We Think You Can Look Beyond Laboratory Corporation of America Holdings' (NYSE:LH) Lackluster Earnings

Feb 22

An Intrinsic Calculation For Laboratory Corporation of America Holdings (NYSE:LH) Suggests It's 48% Undervalued

Feb 21

Laboratory Corporation of America Holdings (NYSE:LH) Has Affirmed Its Dividend Of $0.72

Jan 31

Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly

Jan 30

Laboratory Corporation of America Holdings' (NYSE:LH) Dividend Will Be $0.72

Jan 15

Some Shareholders Feeling Restless Over Laboratory Corporation of America Holdings' (NYSE:LH) P/E Ratio

Jan 05

Newsflash: Laboratory Corporation of America Holdings (NYSE:LH) Analysts Have Been Trimming Their Revenue Forecasts

Jul 04

Are Investors Undervaluing Laboratory Corporation of America Holdings (NYSE:LH) By 43%?

Jun 23

Laboratory Corporation: Predictability Of Cash Flows Less Visible

Jun 21

Is It Too Late To Consider Buying Laboratory Corporation of America Holdings (NYSE:LH)?

May 26

Laboratory Corporation of America Holdings' (NYSE:LH) Returns On Capital Are Heading Higher

Mar 16

Laboratory Corporation of America Holdings (NYSE:LH) Shares Could Be 32% Below Their Intrinsic Value Estimate

Mar 02

Laboratory Corporation of America Non-GAAP EPS of $4.14 in-line, revenue of $3.7B misses by $40M, introduces FY23 outlook

Feb 16

At US$254, Is It Time To Put Laboratory Corporation of America Holdings (NYSE:LH) On Your Watch List?

Jan 30

Laboratory Corporation: Plenty Of Growth Runway

Jan 19

Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly

Jan 16

Laboratory Corporation of America declares $0.72 dividend

Jan 12

Returns At Laboratory Corporation of America Holdings (NYSE:LH) Are On The Way Up

Dec 07

Is There An Opportunity With Laboratory Corporation of America Holdings' (NYSE:LH) 25% Undervaluation?

Nov 24

Laboratory Corporation: Buy Rating Holds Following Solid Mid-Level Growth

Nov 08

Laboratory Corporation of America Q3 2022 Earnings Preview

Oct 26

We Think Laboratory Corporation of America Holdings (NYSE:LH) Can Stay On Top Of Its Debt

Oct 14

Laboratory Corporation of America declares $0.72 dividend

Oct 12

Is Laboratory Corporation of America Holdings (NYSE:LH) Potentially Undervalued?

Sep 28

Previsiones de crecimiento de beneficios e ingresos

NYSE:LH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	14,058	1,215	1,502	2,023	9
12/31/2025	13,429	1,113	1,313	1,772	15
12/31/2024	12,807	982	1,069	1,543	15
3/31/2024	12,300	399	767	1,276	N/A
12/31/2023	12,162	379	874	1,328	N/A
9/30/2023	12,058	583	913	1,298	N/A
6/30/2023	11,868	677	910	1,273	N/A
3/31/2023	11,757	789	1,122	1,513	N/A
12/31/2022	11,864	1,002	1,417	1,847	N/A
9/30/2022	12,990	1,518	1,415	1,895	N/A
6/30/2022	14,186	1,829	1,788	2,303	N/A
3/31/2022	15,104	2,028	1,826	2,308	N/A
12/31/2021	13,136	2,195	2,597	3,018	N/A
9/30/2021	16,555	2,763	2,777	3,187	N/A
6/30/2021	16,388	2,879	2,836	3,206	N/A
3/31/2021	15,316	2,643	2,719	3,089	N/A
12/31/2020	13,979	1,556	1,754	2,135	N/A
9/30/2020	12,442	845	1,520	1,931	N/A
6/30/2020	11,475	362	1,174	1,600	N/A
3/31/2020	11,587	321	1,070	1,483	N/A
12/31/2019	11,555	824	1,045	1,445	N/A
9/30/2019	11,389	755	967	1,361	N/A
6/30/2019	11,292	853	758	1,158	N/A
3/31/2019	11,276	896	890	1,292	N/A
12/31/2018	11,333	884	926	1,305	N/A
9/30/2018	11,291	1,414	1,030	1,384	N/A
6/30/2018	11,081	1,266	1,198	1,529	N/A
3/31/2018	10,743	1,217	1,137	1,452	N/A
12/31/2017	10,308	1,227	N/A	1,498	N/A
9/30/2017	9,951	724	N/A	1,382	N/A
6/30/2017	9,702	732	N/A	1,235	N/A
3/31/2017	9,556	751	N/A	1,274	N/A
12/31/2016	9,553	712	N/A	1,197	N/A
9/30/2016	9,295	658	N/A	1,112	N/A
6/30/2016	9,192	633	N/A	1,150	N/A
3/31/2016	9,029	599	N/A	1,197	N/A
12/31/2015	8,506	438	N/A	982	N/A
9/30/2015	7,774	447	N/A	812	N/A
6/30/2015	7,056	430	N/A	699	N/A
3/31/2015	6,353	401	N/A	510	N/A
12/31/2014	6,012	511	N/A	739	N/A
9/30/2014	5,936	518	N/A	774	N/A
6/30/2014	5,846	529	N/A	833	N/A
3/31/2014	5,798	540	N/A	763	N/A
12/31/2013	5,808	574	N/A	819	N/A
9/30/2013	5,777	568	N/A	824	N/A
6/30/2013	5,734	567	N/A	794	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (24.6% al año) de LH es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (24.6% al año) de LH crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de LH crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (4.4% al año) de LH crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 4.4% al año) de LH crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de LH sea baja dentro de 3 años (15.9%).

Laboratory Corporation of America Holdings Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 17%

Consensus revenue estimates fall by 14%

Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023

Recent updates

Laboratory Corporation of America Holdings (NYSE:LH) Is Paying Out A Dividend Of $0.72

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Dividend of US$0.72 announced

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings' (NYSE:LH) P/E Is On The Mark

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation: A Healthier Diagnosis, As Pandemic Headwinds Disappear

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Executive VP notifies of intention to sell stock

Labcorp Launches Weight Loss Management Testing Solutions

Laboratory Corporation of America Holdings (NYSE:LH) Will Pay A Dividend Of $0.72

CFO & Executive VP recently sold US$4.4m worth of stock

We Think You Can Look Beyond Laboratory Corporation of America Holdings' (NYSE:LH) Lackluster Earnings

An Intrinsic Calculation For Laboratory Corporation of America Holdings (NYSE:LH) Suggests It's 48% Undervalued

Upcoming dividend of US$0.72 per share

Full year 2023 earnings: EPS misses analyst expectations

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) Has Affirmed Its Dividend Of $0.72

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Laboratory Corporation of America Holdings' (NYSE:LH) Dividend Will Be $0.72

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Some Shareholders Feeling Restless Over Laboratory Corporation of America Holdings' (NYSE:LH) P/E Ratio

Laboratory Corporation: Multiple Updates, Same Investment Conclusion

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Upcoming dividend of US$0.72 per share at 1.5% yield

New minor risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Labcorp Declares a Cash Dividend, Payable on December 12, 2023

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc.

Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023

Laboratory Corp.: Rate On Capital Deployed Contracting, Hold

Independent Director recently sold US$1.1m worth of stock

Independent Director notifies of intention to sell stock

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc.

Upcoming dividend of US$0.72 per share at 1.3% yield

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health.

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company.

Consensus revenue estimates decrease by 17%

Laboratory Corporation: Trying To Create Value By Spinning Out Fortrea

Consensus revenue estimates fall by 14%

Newsflash: Laboratory Corporation of America Holdings (NYSE:LH) Analysts Have Been Trimming Their Revenue Forecasts

Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023

Are Investors Undervaluing Laboratory Corporation of America Holdings (NYSE:LH) By 43%?

Laboratory Corporation: Predictability Of Cash Flows Less Visible

Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board

Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus

Is It Too Late To Consider Buying Laboratory Corporation of America Holdings (NYSE:LH)?

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire the outreach laboratory business and select assets of Providence Health & Services - Oregon.

Upcoming dividend of US$0.72 per share at 1.3% yield

Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Laboratory Corporation of America Holdings' (NYSE:LH) Returns On Capital Are Heading Higher

Executive VP & Chief Marketing Officer exercised options and sold US$90k worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) Shares Could Be 32% Below Their Intrinsic Value Estimate

Insider recently sold US$1.3m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023

Laboratory Corporation of America Non-GAAP EPS of $4.14 in-line, revenue of $3.7B misses by $40M, introduces FY23 outlook